Investing.com - Matinas BioPharma (NYSE: MTNB) reported first quarter EPS of $-0.0259, better than the analyst estimate of $-0.0265. Revenue for the quarter came in at $1.03M versus the consensus estimate of $1.02M.
Matinas BioPharma's stock price closed at $0.4400. It is down -22.0800% in the last 3 months and down -20.7200% in the last 12 months.
Matinas BioPharma saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Matinas BioPharma's stock price’s past reactions to earnings here.
According to InvestingPro, Matinas BioPharma's Financial Health score is "fair performance".
Check out Matinas BioPharma's recent earnings performance, and Matinas BioPharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar